[go: up one dir, main page]

PE20071114A1 - Compuestos de tiazol como agentes moduladores de pkb - Google Patents

Compuestos de tiazol como agentes moduladores de pkb

Info

Publication number
PE20071114A1
PE20071114A1 PE2007000057A PE2007000057A PE20071114A1 PE 20071114 A1 PE20071114 A1 PE 20071114A1 PE 2007000057 A PE2007000057 A PE 2007000057A PE 2007000057 A PE2007000057 A PE 2007000057A PE 20071114 A1 PE20071114 A1 PE 20071114A1
Authority
PE
Peru
Prior art keywords
alkyl
thiazol
aryl
pkb
indazol
Prior art date
Application number
PE2007000057A
Other languages
English (en)
Inventor
Qingping Zeng
John Gordon Allen
Matthew Paul Bourbeau
Celia Dominguez
Christopher Fotsch
Nianhe Han
Fang-Tsao Hong
Xin Huang
Matthew Randolph Lee
Aiwen Li
Qingyian Liu
James Rider
Seifu Tadesse
Andrew Tasker
Vellarkad Narayana Viswanadhan
Xianghong Wang
Kurt Edward Weiler
George Erich Wohlhieter
Guomin Yao
Chester Chenguang Yuan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20071114A1 publication Critical patent/PE20071114A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO DE TIAZOL DE FORMULA (I), DONDE A ES -(C)nR3R4-Y O ARILO; Y ES N(R5)R6 O -OR6; X ES O, S O N(R7); R1 ES R8, CHR11, OR8, ENTRE OTROS; R2 ES ARILO O HETEROARILO; R3 ES H, ALQUILO C2-C6, ENTRE OTROS; R4 ES ALQUILO C1-C6, (CR9R10)t(ARILO), ENTRE OTROS; R5 ES H, ALQUILO C1-C8, C(O)(R9R10)t, ENTRE OTROS; R6 Y R7 SON H, ALQUILO C1-C8, C(O)(ALQUILO C1-C6), ENTRE OTROS; R8 ES H, ALQUILO C1-C6, ARILO, ENTRE OTROS; R9, R10 Y R11 SON H, ALQUILO C1-C6 O ARILO; n ES UN ENTERO DE 1 A 6; t ES UN ENTERO DE 0 A 3. SON COMPUESTOS PREFERIDOS: N-((S)-2-AMINO-3-FENILPROPIL)5-(3-METIL-1H-INDAZOL-5-IL)TIAZOL-2-AMINA, N-((S)-2-AMINO-3-(1H-INDOL-3-IL)PROPIL)-5-(3-METIL-1H-INDAZOL-5-IL)TIAZOL-2-AMINA, N-((S)-2-AMINO-3-(4-CLOROFENIL)PROPIL)-5-(3-METIL-1H-INDAZOL-5-IL)TIAZOL-2-AMINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE QUINASA B (PKB) Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON EL CRECIMIENTO CELULAR ANORMAL, CANCER, INFLAMACION, TRASTORNOS METABOLICOS, ENTRE OTROS
PE2007000057A 2006-01-18 2007-01-18 Compuestos de tiazol como agentes moduladores de pkb PE20071114A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954606P 2006-01-18 2006-01-18

Publications (1)

Publication Number Publication Date
PE20071114A1 true PE20071114A1 (es) 2008-01-10

Family

ID=38180602

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000057A PE20071114A1 (es) 2006-01-18 2007-01-18 Compuestos de tiazol como agentes moduladores de pkb

Country Status (21)

Country Link
US (2) US7514566B2 (es)
EP (1) EP1981884B1 (es)
JP (1) JP5199885B2 (es)
KR (1) KR20080091369A (es)
CN (1) CN101421265A (es)
AR (1) AR059064A1 (es)
AU (1) AU2007207743B2 (es)
BR (1) BRPI0706621A2 (es)
CA (1) CA2636077C (es)
CR (1) CR10211A (es)
EA (1) EA200801716A1 (es)
ES (1) ES2389062T3 (es)
IL (1) IL192751A0 (es)
MY (1) MY149143A (es)
NO (1) NO20083572L (es)
PE (1) PE20071114A1 (es)
TW (1) TW200738657A (es)
UA (1) UA91895C2 (es)
UY (1) UY30098A1 (es)
WO (1) WO2007084391A2 (es)
ZA (1) ZA200806386B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354944B2 (en) * 2004-10-18 2008-04-08 Amgen Inc. Thiadiazole compounds and methods of use
KR20080091369A (ko) 2006-01-18 2008-10-10 암젠 인크 단백질 키나제 ｂ （ｐｋｂ） 억제제로서 티아졸 화합물
JP2010518159A (ja) * 2007-02-13 2010-05-27 シェーリング コーポレイション 機能選択性α２Ｃアドレナリン受容体アゴニスト
JP2010533715A (ja) 2007-07-17 2010-10-28 アムジエン・インコーポレーテツド 複素環系ｐｋｂ調節剤
CA2693473A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20110092423A1 (en) * 2008-06-26 2011-04-21 GlaxoSmithKline, LLC INHIBITORS OF Akt ACTIVITY
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
AU2009283195A1 (en) * 2008-08-18 2010-02-25 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
EP3135672B9 (en) * 2008-10-10 2020-05-20 VM Discovery, Inc. Compositions and methods for treating alcohol use disorders, pain and other diseases
PE20120334A1 (es) * 2008-12-19 2012-04-16 Abbott Lab COMPUESTOS HETEROCICLICOS INHIBIDORES DE LAS PROTEINAS ANTI-APOPTOTICAS Bcl2
WO2010083246A1 (en) * 2009-01-15 2010-07-22 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
HRP20171415T4 (hr) 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
CN102647908B (zh) * 2009-10-08 2014-02-19 葛兰素史密斯克莱有限责任公司 组合
EA022982B1 (ru) * 2009-10-08 2016-04-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинация для лечения рака или предраковых синдромов
BR112012008519A2 (pt) * 2009-10-12 2016-04-05 Glaxosmithkline Llc combinação
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
WO2011115071A1 (ja) * 2010-03-15 2011-09-22 国立大学法人広島大学 チエノピリジン誘導体及びその製造方法、並びにそれを用いた有機半導体デバイス
JP5578705B2 (ja) * 2010-03-29 2014-08-27 公益財団法人相模中央化学研究所 （アリール）ジフルオロ酢酸エステル誘導体及びその製造方法
MX2012012052A (es) * 2010-04-16 2013-03-21 Abbvie Inc Inhibidores de ftalazin-(2h)-ona de cinasas.
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US20130102605A1 (en) * 2010-04-23 2013-04-25 Peng Liang Inhibitors of akt activity
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
RS58326B1 (sr) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
CN103304468A (zh) * 2012-03-13 2013-09-18 华东师范大学 一种氧化吲哚的一锅法串联合成方法
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
AU2013285081B2 (en) 2012-07-04 2017-01-12 Rhizen Pharmaceuticals Sa Selective PI3K delta inhibitors
EP2958902B1 (en) 2013-02-19 2017-11-15 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
KR20150127249A (ko) * 2013-03-13 2015-11-16 보스톤 바이오메디칼, 인크. 암 치료를 위한 암 줄기세포 경로 키나아제의 저해제로서 3-(아릴 또는 헤테로아릴)메틸렌인돌린-2-온 유도체
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
EP4039256A1 (en) 2013-11-11 2022-08-10 Amgen Inc. Combination therapy including an mdm2 inhibitor and dasatinib or nilotinib for the treatment of chronic myeloid leukemia
TN2017000374A1 (en) * 2015-03-02 2019-01-16 Bristol Myers Squibb Co TGF-β INHIBITORS
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10858355B2 (en) * 2016-03-10 2020-12-08 Astrazeneca Ab Inhibitors of phosphatidylinositol 3-kinase gamma
BR112019019555A2 (pt) 2017-03-30 2020-04-22 Hoffmann La Roche composto de fórmula i, composição farmacêutica, método de inibição de hpk1, método para melhorar uma resposta imune, método para tratar um distúrbio e uso do composto
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
RS63581B1 (sr) 2017-10-05 2022-10-31 Fulcrum Therapeutics Inc Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju lečenja fshd
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
CN112601584A (zh) 2018-07-24 2021-04-02 豪夫迈·罗氏有限公司 异喹啉化合物及其用途
KR20250171404A (ko) 2018-08-31 2025-12-08 암젠 인크 Mdm2 억제제의 제조 방법
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CA3140392A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
CA3147276A1 (en) * 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
EP4045047A1 (en) 2019-10-15 2022-08-24 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021126816A1 (en) 2019-12-16 2021-06-24 Amgen Inc. Dosing regimen of a kras g12c inhibitor
US12178902B1 (en) 2020-01-12 2024-12-31 University Of Southern California Methods and compositions for fluid drainage by Piezo ion channel activation
CN111603466B (zh) * 2020-06-29 2022-07-22 江南大学 一种乙酮类化合物在制备治疗肿瘤药物中的应用
CN114014787B (zh) * 2022-01-10 2022-03-22 苏州开元民生科技股份有限公司 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591600A (en) * 1969-07-07 1971-07-06 Stauffer Chemical Co 2-aminothiazole phosphates and phosphonates
GB1435139A (en) * 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
JPS5239827B2 (es) 1973-11-08 1977-10-07
US4086239A (en) * 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
DK150068C (da) 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
US4297365A (en) * 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
US4451471A (en) * 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
FR2511375A1 (fr) * 1981-08-17 1983-02-18 Rhone Poulenc Sante Nouveaux derives de la cephalosporine, leur preparation et les medicaments qui les contiennent
DE3630732A1 (de) * 1986-09-10 1988-03-17 Bayer Ag 2-cyano-2-alkoximino-acetamide
US5232921A (en) * 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
JPH0753666B2 (ja) 1987-09-14 1995-06-07 久光製薬株式会社 置換ジフェニルチアゾール誘導体からなる抗炎症剤
FR2636628B1 (fr) * 1988-08-25 1990-12-28 Sanofi Sa Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant
US5302608A (en) * 1988-11-18 1994-04-12 Takeda Chemical Industries, Ltd. Age formation inhibitors
US5145860A (en) * 1989-01-05 1992-09-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
DE69526958T2 (de) * 1994-11-29 2003-01-16 Hisamitsu Pharmaceutical Co., Inc. Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
EP1087951B9 (en) 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
WO2000045635A1 (en) 1999-02-08 2000-08-10 Lion Bioscience Ag Thiazole derivatives and combinatorial libraries thereof
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001114690A (ja) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd ｐ３８ＭＡＰキナーゼ阻害剤
EP1205478A4 (en) * 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
WO2001074811A2 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US7074934B2 (en) * 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
JP4689801B2 (ja) 2000-08-09 2011-05-25 ケミプロ化成株式会社 アミノチアゾール誘導体の製造方法
JP2002053566A (ja) * 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
GB0114185D0 (en) * 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
AR032653A1 (es) * 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
ATE315555T1 (de) * 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
US20050080113A1 (en) * 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
IL161092A0 (en) * 2001-09-28 2004-08-31 Cyclacel Ltd N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds
GB0123589D0 (en) * 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
WO2003039451A2 (en) * 2001-11-08 2003-05-15 Fujisawa Pharmaceutical Co., Ltd. Thiazole pyridazinones as adenosine antagonists
CN1633293A (zh) 2002-02-13 2005-06-29 药物基因实验室有限公司 5－ht2b受体拮抗剂
ATE373654T1 (de) 2002-02-28 2007-10-15 Hoffmann La Roche Thiazolderivate als npy-rezeptorantagonisten
TWI314928B (en) * 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
WO2004026226A2 (en) * 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
CN1688557A (zh) * 2002-10-09 2005-10-26 辉瑞产品公司 用于治疗神经变性疾病的噻唑化合物
NZ540161A (en) 2002-10-30 2008-03-28 Vertex Pharma Compositions useful as inhibitors of rock and other protein kinases
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
FR2850380B1 (fr) * 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7157476B2 (en) 2003-08-20 2007-01-02 Vertex Pharmaceuticals Incorporated Aminofurazan compounds useful as protein kinase inhibitors
MXPA06002567A (es) * 2003-09-06 2006-09-04 Vertex Pharma Moduladores de transportadores con casete de union de atp.
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
RS50521B (sr) 2004-01-12 2010-05-07 Applied Research Systems Ars Holding N.V. Derivati tiazola i njihova upotreba
CA2551142A1 (fr) * 2004-01-16 2005-08-11 Sanofi-Aventis Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
PT1709018E (pt) * 2004-01-16 2011-10-24 Sanofi Sa Derivados de acilaminotiazole e sua aplicação como inibidores
US20070185152A1 (en) * 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
US7342118B2 (en) 2004-03-23 2008-03-11 Pfizer Inc Imidazole compounds for the treatment of neurodegenerative disorders
CA2561977A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
US7575751B2 (en) * 2004-04-27 2009-08-18 Research Development Foundation Activin-A mutants
US7893020B2 (en) * 2004-05-21 2011-02-22 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
JP2008509923A (ja) 2004-08-13 2008-04-03 ジェネンテック・インコーポレーテッド Ａｔｐ利用酵素のチアゾールベースのインヒビター
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
US7354944B2 (en) * 2004-10-18 2008-04-08 Amgen Inc. Thiadiazole compounds and methods of use
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
BRPI0607062A2 (pt) * 2005-02-28 2009-08-04 Japan Tobacco Inc composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
CA2612338C (en) * 2005-06-17 2015-02-03 Apogee Biotechnology Corporation Sphingosine kinase inhibitors
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
WO2007066805A1 (ja) 2005-12-09 2007-06-14 Meiji Seika Kaisha, Ltd. リンコマイシン誘導体およびこれを有効成分とする抗菌剤
TW200730476A (en) 2005-12-12 2007-08-16 Genelabs Tech Inc N-(5-membered aromatic ring)-amido anti-viral compounds
KR20080091369A (ko) 2006-01-18 2008-10-10 암젠 인크 단백질 키나제 ｂ （ｐｋｂ） 억제제로서 티아졸 화합물
EP1979338A1 (en) 2006-01-18 2008-10-15 F.Hoffmann-La Roche Ag Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
US7897601B2 (en) 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
BRPI0706621A2 (pt) 2011-04-05
ES2389062T3 (es) 2012-10-22
EP1981884B1 (en) 2012-06-13
IL192751A0 (en) 2009-02-11
UA91895C2 (en) 2010-09-10
US20090270445A1 (en) 2009-10-29
EP1981884A2 (en) 2008-10-22
KR20080091369A (ko) 2008-10-10
CN101421265A (zh) 2009-04-29
UY30098A1 (es) 2007-10-31
CR10211A (es) 2008-10-03
NO20083572L (no) 2008-10-17
AU2007207743A1 (en) 2007-07-26
JP5199885B2 (ja) 2013-05-15
US20070173506A1 (en) 2007-07-26
WO2007084391A3 (en) 2008-03-20
JP2009525960A (ja) 2009-07-16
CA2636077C (en) 2012-01-03
AR059064A1 (es) 2008-03-12
EA200801716A1 (ru) 2009-04-28
ZA200806386B (en) 2009-11-25
WO2007084391A2 (en) 2007-07-26
US7514566B2 (en) 2009-04-07
AU2007207743B2 (en) 2010-07-08
MY149143A (en) 2013-07-15
TW200738657A (en) 2007-10-16
CA2636077A1 (en) 2007-07-26
US8084479B2 (en) 2011-12-27

Similar Documents

Publication Publication Date Title
PE20071114A1 (es) Compuestos de tiazol como agentes moduladores de pkb
PE20090109A1 (es) Compuestos pirrolicos como inhidores de la bomba de protones
GEP20156348B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
PE20140918A1 (es) Compuestos de benzoxepina inhibidores de la pi3k
PE20110931A1 (es) Pirrolidin-2-onas como ligandos de hdm2
PE20081262A1 (es) Derivados de fenilo como moduladores de cinasas y composiciones
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20070602A1 (es) Compuestos de carboxiamina como moduladores de histona desacetilasa
PE20081530A1 (es) Nuevos compuestos 617
ATE433981T1 (de) Heterocyclische verbindungen
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
PE20080091A1 (es) Derivados de cicloalquilamino como agentes moduladores de s1p
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
MX2010006421A (es) Compuestos organicos.
PE20081882A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
EA200601896A1 (ru) Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
ATE368031T1 (de) Neue gamma secretase inhibitoren
PE20090042A1 (es) Analogos de ciclopamina
PE20091349A1 (es) Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed